ArticleScientific reports2024
Utilization of RESOLV with polymer to produce prazosin hydrochloride nanoparticles and optimization of the process parameters.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, rapid expansion of a supercritical solution into a Liquid Solvent (RESOLV) was used for the first time to produce pharmaceutical nanoparticles of Prazosin hydrochloride (PRH). The Taguchi method (robust design) was utilized to design the experiments and ensure obtaining the optimal process conditions. The pressure (15-25 MPa), temperature (308-328 K) and nozzle diameter (300-700 μm) effects on the morphology and size distribution of the resulting particles were also examined. The size of the particles decreased from about 40 μm to the range of (252-418 nm). FTIR, DLS, FESEM, XRD, DSC were used to characterize the primary and processed PRH particles. According to DSC investigations, RESOLV-produced PRH showed lower crystallinity than original PRH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.